The suicide substrate reaction between plasminogen activator inhibitor 1 and thrombin is regulated by the cofactors vitronectin and heparin van Meijer, M; Smilde, A.E.; Tans, G.; Nesheim, M.E.; Pannekoek, H.; Horrevoets, A.J.G.
The interaction of thrombin with plasminogen activator inof inhibition, both cofactors increase the apparent stoichihibitor 1 (PAI-1) is shown to result in the simultaneous forometry of the PAI-1-thrombin interaction, with cofactor mation of both cleaved PAI-1 and a sodium dodecyl sulfateconcentration dependencies similar to the inhibition reacstable thrombin-PAI-1 complex. The kinetics of this reaction tion. Thus, at 37ЊC approximately six cleavage reactions occan be described by a ''suicide substrate'' mechanism that cur per inhibition reaction. Therefore, thrombin will effiincludes a branched reaction pathway, which terminates in ciently inactivate PAI-1 in the presence of either vitronectin either the stable inhibitor-enzyme complex or the cleaved or heparin, unless a sufficient excess of the inhibitor is presinhibitor plus free enzyme. Because of the branched pathent. These results show that physiological cofactors are able way, approximately three moles of PAI-1 are needed to comto switch a protease-serpin inhibition reaction to a substrate pletely inhibit one mole of thrombin. Heparin and vitronectin reaction, depending on the local concentrations of each of enhance the rate of inhibition from 9.8 Ì 10 2 L mol Ï1 s Ï1 to the components. 6.2 Ì 10 4 L mol Ï1 s Ï1 and 2.1 Ì 10 5 L mol Ï1 s Ï1 , respectively, ᭧ 1997 by The American Society of Hematology. under optimal conditions. In addition to enhancing the rate P provided by mutagenesis experiments: deletion of VR1 or replacement of the positively charged residues of VR1 by LASMINOGEN activator inhibitor 1 (PAI-1) 1 is the main physiological inhibitor of both tissue-type (t-PA) negative ones, reduced the second-order rate constant of inhiand urokinase-type (u-PA) plasminogen activator 1 and bebition for this reaction by at least three orders of magnitude longs to the 'serpin' superfamily of homologous proteins. [2] [3] [4] [5] (from 2 1 10 7 to°10 4 L mol 01 s
01
). 10 Consistent with these Thrombin is inhibited by PAI-1 at a slow rate, but we have data, we showed that a thrombin variant having its entire described that the cofactors heparin and vitronectin increase variable region 1 substituted by that of t-PA (thrombin-VR1), this rate by about two orders of magnitude. 6, 7 The physiologishowed a 2,000-fold increased rate of inhibition by PAIcal relevance of this finding was shown in the endothelial 1. 13 In this case, as with native thrombin, substantial PAI-1 cell matrix (ECM), where efficient thrombin/PAI-1 complex cleavage was observed during the time course of inhibition. formation is strongly dependent on the presence of endogeIn contrast to the inhibition of native thrombin by PAI-1, nous vitronectin. 8 Experiments performed with metabolically thrombin-VR1 inhibition is only marginally influenced by labeled ECM showed that addition of thrombin, t-PA or uthe presence of cofactors. PA to the ECM resulted not only in the formation of sodium
The interaction of a serpin with its target protease has dodecyl sulfate (SDS)-stable PAI-1/protease complexes, but been suggested to occur via the branched pathway of a soalso in proteolytically cleaved PAI-1. 8 Apparently, in this called suicide substrate mechanism. 14-16 In the 'substrate' setting PAI-1 can be cleaved, either before or after complex pathway, the serpin acts as a substrate, ultimately leading to formation with these proteases.
cleaved inhibitor and the release of active protease. Cleavage The interaction of t-PA with PAI-1, which has been studof the inhibitor occurs between the reactive site P 1 and P 1 ied in great detail, is dependent on the presence of a posiresidues on an exposed surface loop, located about 30 resitively charged variable region (VR1) on the protease domain dues from the C-terminus. In the 'inhibition' pathway preof t-PA, which presumably interacts with negatively charged sumably reversible complex formation also occurs but at residues on PAI-1. [9] [10] [11] [12] Evidence of the importance of the some point the reaction is arrested, resulting in the formation VR1 domain of t-PA for the interaction with PAI-1 was of a SDS-stable, inactive serpin-protease complex. Within this complex, ultimate cleavage of the inhibitor is very slow and, consequently, in vivo the complexes will be cleared centrations in a fluorimeter microcuvette (Hellma Benelux, Rijswijk, EXPERIMENTAL PROCEDURES the Netherlands). The inhibition reaction was started by the addition Materials. Unfractionated heparin from porcine intestinal muof a small volume of PAI-1 and the reaction was monitored continucosa (# H-3125, grade I, Lot 29F-0314; specific activity of 178 U/ ously until no further change in fluorescence intensity was observed. mg, average Mr of 15,000 to 18,000) and hirudin were obtained Alternatively, the inhibition reaction was stopped after approxifrom Sigma (St Louis, MO). The chromogenic substrates CH 3 SO 2 -mately 10 minutes by the addition of 0.5 mL of 3.2 mmol/L of D-HHT-Gly-Arg-p-nitroanilide (Pefachrome tPA) and H-D-Phethe active-site directed irreversible thrombin inhibitor PPACK to Pip-Arg-p-nitroanilide (where Pip is pipecolic acid; S2238) were determine the maximal change in fluorescence intensity. Initial reacobtained from Pentapharm (Basel, Switzerland) and Chromogenix tion rates of thrombin inhibition were calculated from the slope of (Mölndal, Sweden), respectively. The fluorescent active-site dia plot of fluorescence intensity versus time. The initial reaction rected, reversible inhibitor of thrombin Dansylarginine N-(3-Ethylrate equals: T o *slope/(F i 0F o ), in which T o represents total thrombin 1,5-pentanediyl)amide (DAPA) was prepared as described. 26 The concentration, F i is the initial fluorescence intensity at time zero, and irreversible active-site directed thrombin inhibitor Phe-Pro-Arg-F o is the fluorescence intensity at complete inhibition. Alternatively, Chloromethyl-ketone (PPACK) was obtained from Calbiochem (San initial reaction rates were determined by fitting inhibition curves Diego, CA Determination of the apparent stoichiometry. The apparent stoi-(Hoefer Scientific Instruments, San Francisco, CA). Proteins were chiometry for the interaction of PAI-1 with thrombin, thrombinstained with Coomassie Brilliant Blue (GIBCO-BRL) and reaction VR1, or t-PA was determined by titration of the enzyme with stepproducts were quantified by laser densitometry. At identical time wise increased concentrations of PAI-1 as described in detail. 7 These points, 20 mL aliquots were withdrawn and the reaction was titrations were performed for various times (between 1.5 and 18 quenched by adding the aliquots to 680 mL 0.5 mmol/L of the hours) at 37ЊC with various concentrations (between 2 and 100 nmol/ chromogenic substrate S2238. Residual thrombin amidolytic activity L) of either thrombin, thrombin-VR1, or t-PA in a volume of 25 mL in these aliquots was measured at 37ЊC after a 25-fold dilution of HBST buffer. The incubation times used were determined from in HBST buffer, containing 0.5 mmol/L S2238, by continuously calculations using known inhibition rate constants. Control experirecording the absorbance at 405 nm in a Titertek Twinreader (Flow ments indicated that these incubation times were sufficient for comLaboratories, Irvine, UK).
pletion of the reaction. In all cases, a control incubation containing Fluorometric assay for thrombin inhibition. The reaction beno inhibitor was included. In some reactions, various concentrations tween thrombin and PAI-1 was monitored by including the fluoresof vitronectin or heparin were included. Residual protease activity cent, reversible thrombin inhibitor DAPA 26 in the reaction solution was subsequently determined at 37ЊC by the addition of a sample as described. 30 Traditional progress curve analysis could not be perto a mixture of 150 mL HBST buffer and 25 mL of 4 mmol/L of formed, since PAI-1 is rapidly inactivated by a number of chromothe chromogenic substrate S2238 (thrombin or thrombin-VR1) or Pefachrome tPA (t-PA), respectively, by measuring the increase in genic substrates tested (Van Meijer M. and Horrevoets A.J.G., unabsorbance at 405 nm in a Titertek Twinreader. Results were plotted published observations, March 1993, and ref 31) . Fluorescence as the fraction of residual enzyme activity versus the initial inhibitor intensity was measured at 37ЊC with a Perkin-Elmer LS-50 fluorimconcentration. The intercept on the abscissa is the apparent stoichieter (Norwalk, CT). The excitation wavelength was 280 nm with a ometry of the reaction, being equal to 1 / the partition ratio (r). 15 band pass of 10 nm, the emission wavelength was 565 nm with a This partition ratio (k 3 /k 4 , see Fig 1) represents the number of cata-15-nm band pass, using a 430-nm cut-off filter in the emission beam.
lytic turnovers per inactivation event. The dissociation constant (kd) for DAPA of the thrombin used in this study was determined to be 63.5 nmol/L. 26 Briefly, a solution RESULTS of thrombin (final concentration of 18.6 nmol/L or 36.6 nmol/L) of the time course of inhibition of thrombin by PAI-1 shows and PAI-1 and the appearance of the different species was followed for a time period much longer than the time needed the appearance of cleaved inhibitor, in addition to stable complex formation (Fig 1A) . This observation can be exto inhibit all thrombin present. The reaction products seen on the gel were quantified using laser densitometry ( Fig 1A  plained by two different reaction pathways: (1) after formation of the SDS-stable complex, hydrolysis of the complex and B). Complex formation and cleavage of PAI-1 clearly occur simultaneously during the reaction as depicted by the results in release of active enzyme and cleaved inhibitor, and (2) the serpin can act as a suicide substrate. This means fitted first-order reaction curve for the appearance of both species. The rate of disappearance of the thrombin band that after the formation of the reversible complex, two pathways can be followed: one leading to the formation of the agrees with a second-order rate constant of 9.8 1 10 2 L mol 01 s
Time course of PAI-1 cleavage by thrombin and of throm-

01
, which is consistent with published numbers. As SDS-stable complex (inhibition pathway) and one leading to cleavage of the inhibitor and release of the active enzyme a control, the amidolytic activity of thrombin was determined at similar time points and was shown to decrease with an (substrate pathway) (Fig 2) . To discriminate between these possibilities, the progress of the reaction between thrombin identical second-order rate constant (data not shown). Fur- The apparent stoichiometries were determined by titration at 37ЊC at least in duplicate as described under ''Experimental Procedures.'' Indicated are results obtained at different time points and, when indicated, in the presence of either an optimal heparin concentration (ie, 1 U/mL in case of thrombin (502.5 nmol/L) inhibition, and 0.5 U/mL in case of thrombin-VR1 (20 nmol/L inhibition), or 200 nmol/L vitronectin.
thermore, the concentration of cleaved inhibitor remained stable during a further 19 hours incubation without reappearance of free active thrombin and little degradation of the complex was observed. The apparent stoichiometry determined within the experimental limits of gel quantitation was about 3, which is in good agreement with the more accurate numbers as determined by titration (Table 1) . Control experiments performed with latent PAI-1, which is unable to complex with thrombin, revealed no cleavage of PAI-1 (data not shown).
Kinetic analysis of cofactor influence on the inhibition pathway. Previous data from our laboratory, 6, 32 suggested that heparin might accelerate the inhibition of thrombin by PAI-1 by acting as a template. In Fig 3 we have now elaborated on these observations by studying this reaction in more detail. This was done by studying these kinetics by means of displacement of the thrombin specific fluorescent inhibitor DAPA from the active site by PAI-1. Traditional progress curve analysis could not be performed, since we observed that PAI-1 is rapidly inactivated by a number of chromogenic substrates tested (data not shown) as has been reported during the progress of these studies by others. 31 Central to the template mechanism is that inhibitor and enzyme are concentrated on the template in a way that favors the interaction. At any fixed concentration of inhibitor and enzyme, an optimum in the inhibition rate with increasing concentrations of heparin is observed. Furthermore, the reaction rate saturates 
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in both proteins at a fixed concentration of heparin.
33 Figure  3A illustrates that increased concentrations of heparin, in the presence of fixed concentrations of thrombin and PAI-1, result in increased initial rates of thrombin inhibition up to a maximum, followed by a decrease in rates. Furthermore, with increasing concentrations of PAI-1, the rate obtained at the peak of the bell-shaped curves, and the heparin concentration required to obtain the maximum, increases. The maximal rate of inhibition accords to a second-order rate constant for inhibition of 6.2 1 10 4 L mol 01 s
01
, representing a 124-fold increase over the rate in the absence of heparin. As shown in Fig 3B, the thrombin inhibition rate saturates at high PAI-1 concentrations, reflecting saturation of the binding sites on heparin with PAI-1. The existence of saturation implies that PAI-1 does not effectively compete with functionally significant bound thrombin. In contrast, when the rate of thrombin inhibition was determined at various thrombin concentrations at fixed concentrations of PAI-1, heparin, and DAPA, the observed rate of inhibition increases up to a maximum and then decreases (Fig 3C) . This decrease in to the thrombin concentration upon saturation of the heparin
template. This occurs when approximately two molecules of thrombin are bound to one heparin molecule. Figure 4 shows the effect of increasing concentrations of vitronectin on the rate of thrombin inhibition by PAI-1. Increasing concentrabin, even in the absence of cofactors. 13 First, we determined tions of vitronectin result in increased rates for inhibition up that the apparent stoichiometry of the PAI-1-protease reacto a maximum. Within the experimentally feasible range of tion is stable in time at 37ЊC for all proteases (Table 1) and concentrations, however, no decrease is observed at higher is independent of protease concentrations (data not shown). concentrations of this cofactor. Apparently, at each of the Second, we determined the cofactor concentration depen-PAI-1 concentrations tested, rates are maximal when all the dence of the cleavage pathway by determining the amount PAI-1 is complexed to vitronectin. In agreement with this of PAI-1 required to inhibit 1 nmol/L of thrombin-VR1. This finding, the maximum rate of thrombin inhibition observed thrombin variant was used for this study, since the inhibition was proportional to the concentration of PAI-1 present. Furrate with native thrombin is too low to perform these experithermore, the rates as a function of the bimolecular PAI-1/ ments with experimentally feasible concentrations of the provitronectin complex at each of the PAI-1 concentrations teins. As shown in Fig 5A , similar to the cofactor dependence could be well fitted with a kd of approximately 50 nmol/L observed for the rate of thrombin inhibition (Fig 3A) , the for the formation of the PAI-1/vitronectin complex and a stoichiometry showed an optimum with respect to the hepasecond-order rate constant for thrombin inhibition by this rin concentration. Moreover, the optimal heparin concentracomplex of 2.1 1 10 5 L mol 01 s 01 (solid lines, Fig 4) . tions are similar, and both pathways show a bell-shaped Distribution of PAI-1 over substrate and inhibition pathprofile (Fig 3A and 5A ). In contrast, as shown in Fig 5B, in ways. In the previous section we have shown that PAI-1 the case of PAI-1 and vitronectin there is a maximum PAI-1 acts as a suicide substrate (Fig 1) . Furthermore, we have cleavage at high vitronectin concentrations. Figure 5B is an shown that the cofactors heparin and vitronectin increase the endpoint titration in which the components are incubated for rate of thrombin inhibition by at least two orders of magnione hour. Therefore, the stoichiometry of PAI-1 to vitronectin tude (Figs 3 and 4) . Initially, we hypothesized that the inis not necessarily 1:1, since vitronectin can be recycled for creased inhibition rates in the presence of the cofactors might another interaction with uncomplexed PAI-1. This result is be the result of protection against PAI-1 cleavage. Therefore, comparable with the relationship of increasing vitronectin conwe monitored the thrombin and, as a control, the t-PA inhibicentrations and maximum initial rate of inhibition (Fig 4) . Next, tion reaction under several conditions. In addition, we used we determined the apparent stoichiometry of native thrombin a thrombin variant, denoted thrombin-VR1, that is inhibited inhibition in the presence of optimal concentrations of the cofactors (Table 1) . Both cofactors increase the apparent stoichithree orders of magnitude faster by PAI-1 than native throm-AID Blood 0031 / 5h3c$$$601 08-01-97 12:13:51 blda WBS: Blood ometry approximately twofold to threefold not only for native thrombin but also for thrombin-VR1. So although cofactors hardly influence the inhibition rate for this variant, they do have the same effect on the partition ratio. In contrast, t-PA inhibition by PAI-1 did not show an increased stoichiometry in the presence of heparin and vitronectin (Table 1) . This demonstrates that the effect of the cofactors on product distribution is specific for thrombin.
DISCUSSION
The data presented in this report show that the inhibition of thrombin by PAI-1 can be described in terms of a suicide substrate mechanism (Fig 2) in which after formation of the bimolecular complex, the enzyme can either be trapped in a SDS-stable complex or can cleave the inhibitor and thereby become available for another catalytic turnover. In agreement with such a mechanism it was found that the kinetics of complex formation and PAI-1 cleavage are virtually identical (Fig 1) , and prolonged incubation of thrombin and PAI-1 (19.5 hours) did not result in detectable release of active thrombin, excluding progressive cleavage of the SDS-stable thrombin/PAI-1 complexes within the experimental time. Thus the value of rate constant k 5 (Fig 2) is negligible. The product distribution of the reaction between thrombin and PAI-1 can be deduced from the apparent stoichiometry of the reaction (Table 1) . Notably, the variant thrombin-VR1, which is inhibited three orders of magnitude faster than thrombin, shows a similar apparent stoichiometry. In contrast, t-PA inhibition by PAI-1 in a purified system shows a 1:1 stoichiometry at 37ЊC, excluding the presence of a ''substrate-form'' of PAI-1 in our preparation.
34
The kinetics of the stimulation of the rate of thrombin inhibition by PAI-1 by the cofactor heparin are fully consistent with a template mechanism as suggested previously by studies from our laboratory. 6, 32 Our data are comparable to those reported on the inhibition of thrombin by antithrombin III in the presence of heparin. 30 In that study it was shown that the enzyme does not interfere with antithrombin III binding to heparin. It should be noted that in that study the heparin was fractionated on immobilized antithrombin III, to select the high affinity subfraction. However, we find competition when two thrombin binding sites are saturated, 35 probably caused by the almost 10-fold lower affinity of PAI-1 for unfractionated heparin compared to antithrombin III. 6 In contrast to the results for heparin, increasing concentrations of vitronectin result in increased rates of inhibition up to a maximum without a decrease at higher concentrations of this cofactor. Thus, within our experimental limits, we did not find evidence that vitronectin would accelerate the thrombin to vitronectin. 36,37 These authors also hypothesized the existence of additional accelerating effects other than a template mechanism. Our data show optimal rates of throm-AID Blood 0031 / 5h3c$$$601 08-01-97 12:13:51 blda WBS: Blood bin inhibition at vitronectin concentrations that are equal to and PAI-1, since in this case the outcome of the reaction can be locally influenced by the cofactors vitronectin and or exceed the PAI-1 concentration, indicating that the increased rate is a reflection of an increased concentration of heparin, both of which increase the thrombin inhibition rate by PAI-1 at the expense of increased PAI-1 consumption the bimolecular PAI-1/vitronectin complex, which is maximized when all PAI-1 is complexed. Apparently, the PAI-1/ through the cleavage pathway. It can be speculated that cleavage of PAI-1 rather than inhibition of thrombin will be vitronectin complex acts as a functionally different inhibitor species than uncomplexed PAI-1, as discussed in more detail the main event occurring in vivo, since the PAI-1 consumption exceeds the amount of complexes formed under most below. A global fit of our data to this reaction mechanism yields a kd of approximately 50 nmol/L for the formation conditions tested. Thus, thrombin will efficiently inactivate PAI-1 in the presence of either vitronectin or heparin, proof the vitronectin/PAI-1 complex. This value inferred by kinetics is comparable with that for the low-affinity PAIvided thrombin is present in sufficient amounts to overcome the minor contribution of the inhibition reaction (1 in 6 1 binding site on vitronectin (kd Å 55 nmol/L), found by equilibrium binding studies. 38 catalytic events). This situation is likely to occur in plasma, where during coagulation high local concentrations of thromPreviously it has been shown that addition of high concentrations of thrombin and heparin to preformed PAI-1/thrombin will be generated. This is particularly relevant in the setting of platelet-rich plasma clots, which are rich in abin complexes results in the appearance of cleaved forms of the complex and PAI-1. 39 However, the molecular weight of granule PAI-1 and thereby thrombolysis resistant. Under these circumstances, high concentrations of thrombin will the cleaved forms of PAI-1 (õ31 kD) were not consistent with cleavage within the reactive center loop. We show for act profibrinolytic by inactivating PAI-1, the inhibitor of the fibrinolytic enzyme t-PA. Therefore, the direct and efficient the first time that the cofactors vitronectin and heparin increase the amount of reactive center loop-cleaved, inactive inhibition of thrombin during thrombolytic therapy as adjunctive therapy to prevent reocclusion, might in fact ad-PAI-1 that is formed during the interaction of thrombin with PAI-1 in addition to their accelerating effect on the formation versely affect thrombolysis, a phenomenon that needs further study. of the inactive PAI-1/thrombin complex. Again, appearance of reactive center loop-cleaved PAI-1 (MW 39 kD; SDSThese findings also have implications for the processes that occur in the vessel wall under (patho)physiological con-PAGE, data not shown) occurs simultaneous to but not after complex formation, consistent with a suicide substrate mechditions. A vast number of studies have shown that the proteins described in this study are synthesized in the vessel wall anism. Apparently, these cofactors have a profound effect on more than one of the individual rate constants that constiunder inflammatory conditions. Specifically, such conditions induce the synthesis and surface exposure of tissue factor tute the suicide substrate mechanism of thrombin/PAI-1 interaction (Fig 2) , since the overall rate of thrombin inhibition by smooth muscle cells, which may ultimately result in the generation of thrombin. 43, 44 Recently, it has been shown that is increased by two orders of magnitude, and cleavage is increased twofold to threefold, as reflected by the increased smooth muscle cells express the specific thrombin receptor, 45 permitting effects of thrombin on smooth muscle cell specific apparent stoichiometry of the reaction (Table 1) .
Recently, time-resolved fluorescence spectroscopy has ingene expression. Furthermore, several laboratories have reported on the induction of PAI-1 synthesis and secretion dicated that binding of the cofactors heparin and vitronectin to PAI-1 induces a conformational change in the reactive by smooth muscle cells by thrombin. 46, 47 Finally, a natural constituent of this cell matrix, namely vitronectin, has recenter of PAI-1. 40 Apparently, the different architecture of the exposed loop upon binding of PAI-1 to one of its cofaccently been shown to promote the clearance of active thrombin in a PAI-1 dependent manner by low density lipoprotein tors makes these amino acid residues more accessible for receptor-related protein-expressing cells. 48 Collectively, the thrombin catalytic center. Our results imply that this those observations suggest a potential ''feed-back'' regulaaltered conformation of the reactive site loop results in both tory mechanism for thrombin activity. The data reported in increased substrate and inhibition reactions in the case of this paper provide a mechanistic concept for the interactions thrombin. The reaction between t-PA with PAI-1 in a puribetween thrombin, PAI-1 and specific cofactors. Therefore, fied system differs from thrombin by the appearance of the relative amounts of active PAI-1 and thrombin at this site, cleaved inhibitor in the latter case. Apparently, the k 4 of twhich might be determined by the outcome of the suicide PA exceeds the k 3 to a great extent, since no cleavage of substrate mechanism, will have important implications for PAI-1 is observed, unless the reaction is performed in the local cellular processes. ECM. 8 An explanation for the difference in the partition ratio between t-PA and thrombin might be that thrombin is REFERENCES a more potent catalyst than t-PA, both for the hydrolysis of ing and sequence of a cDNA coding for the human beta-migrating
The notion that a serpin inhibits its target proteases via a endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad suicide substrate mechanism has profound implications on Sci USA 83:6776, 1986 our understanding and appreciation of this reaction in vivo. 
